Navigation Links
Silence Therapeutics Announces Board Changes and Appointment of New Chief Executive Officer
Date:2/10/2012

shareholder value."

Tony Sedgwick holds 1,108,108 shares (0.19%) of the issued share capital in the Company.  No further disclosures are required under Rule 17 and Schedule 2(g) of the AIM Rules.

Notes for Editors

About Silence Therapeutics plc (www.silence-therapeutics.com)

Silence Therapeutics plc (AIM: SLN) is a leading biotechnology company dedicated to the discovery, development and delivery of targeted, systemic RNA interference (RNAi) therapeutics for the treatment of serious diseases. Silence offers one of the most comprehensive short interfering RNA (siRNA) therapeutic platforms available today based on a strong intellectual property portfolio and large clinical safety database. Silence's clinical siRNA product pipeline is one of the broadest in the industry. The Company possesses multiple proprietary siRNA delivery technology platforms including AtuPLEX™, DACC and DBTC. AtuPLEX enables the broad functional delivery of siRNA molecules to targeted diseased tissues and cells, while increasing their bioavailability and intracellular uptake. The DACC delivery system allows functional delivery of siRNA molecules selectively to the lung endothelium with a long duration of target mRNA and protein knock-down. The DBTC delivery system enables functional delivery of siRNA molecules selectively to liver cells including hepatocytes. Additionally, the Company has a platform of novel siRNA molecules based around its AtuRNAi chemical modification technology, which provides a number of advantages over conventional siRNA molecules. Silence's unique RNAi assets also include structural features for RNAi molecules and specific design rules for increased potency and reduced off-target effects of siRNA sequences.

The Company's lead internal drug candidate is Atu027, a liposomal formulation in clinical development for systemic cancer indications and o
'/>"/>

SOURCE Silence Therapeutics Plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Silence Therapeutics Additional Listing
2. Silence Therapeutics Announces Positive Response by USPTO that Affirms Validity of Four Foundational RNAi Patents
3. Silence Therapeutics Announces Positive Outcome From Oral Hearing at the European Patent Office
4. Silence Therapeutics Provides Corporate and Development Update
5. Silence Therapeutics Signs Collaboration With Mirna Therapeutics to Evaluate Delivery of Novel microRNA Therapeutics
6. Silence Therapeutics Issued Japanese Patent Covering its Core RNA Interference (RNAi) Technology
7. Silence Therapeutics Lead RNA Interference Therapeutic Prevents Spread of Cancer to Lungs
8. Silence Therapeutics Receives Comprehensive Protection for RNAi Structural Modification Technology in Single European Patent
9. Silence Therapeutics Partner Quark Signs Exclusive Option Agreement With Novartis for Development and Commercialisation of QPI-1002
10. Silence Therapeutics Expands RNAi Structural Modification IP Portfolio With Issuance of New U.S. Patent
11. Silence Therapeutics Issued Novel RNAi Patent Covering High-Value Cancer Target in United States
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... September 24 marks ASEA's "Meet ASEA" grand ... manufacturer of the world's first and only redox signaling ... , The Mexico City event features renowned speakers Dr. ... Field Leader Shawn Catmull from Draper, UT. , Dr. ... from the University of Utah and devotes his career ...
(Date:9/17/2014)... Sept. 17, 2014 /PRNewswire/ - Oncothyreon Inc. (NASDAQ: ... offer and sell shares of its Common Stock and ... underwritten public offerings.  The Series A Convertible Preferred Stock ... Stock, provided that conversion will be prohibited if, as ... own more than 4.99% of the Common Stock then ...
(Date:9/17/2014)... 2014 A biodegradable polymer can ... as bacteria, fungi, and algae into smaller units ... inorganic compounds, carbon dioxide, and humus in a ... and improved costs, biodegradable polymers are proving to ... to conventional polymers. Primary factors that are responsible ...
(Date:9/17/2014)... Sept. 17, 2014 Intarcia Therapeutics, Inc. ... from a study of the cost and predictability of ... th Annual Meeting of the European Association for ... today, Christian Frois , Ph.D., of Analysis Group, ... of planned Intarcia-sponsored, retrospective studies to characterize the prevalence ...
Breaking Biology Technology:Announcing the ASEA Mexico Grand Opening Tour Beginning September 18th 2Oncothyreon Announces Proposed Public Offerings 2Growing Demand for Eco-Friendly Products Drives the Global Biodegradable Polymers Market, According to New Report by Global Industry Analysts, Inc. 2Growing Demand for Eco-Friendly Products Drives the Global Biodegradable Polymers Market, According to New Report by Global Industry Analysts, Inc. 3Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 2Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 3Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 4Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 5
... 17 Initial public offerings for LinkedIn and Dunkin Donuts, takeovers of Mead Johnson Nutrition and Harley-Davidson, and a Cold Stone Creamery sale are among the 10 deals predicted by ... ... ... ...
... , March 17 Valeritas, Inc., a medical technology company committed to the development and commercialization of innovative drug delivery solutions, announced today that it has hired James ... ... ... ...
... ... Converting to 3D Imaging , ... Thornwood, N.Y. (PRWEB) March 17, 2010 -- Carl Zeiss, a leading provider ... recently announced two exciting online promotions. For a limited time, and only available online, ...
Cached Biology Technology:From Donuts To Hogs - Which Brand Icons Might Be In Play? 2From Donuts To Hogs - Which Brand Icons Might Be In Play? 3From Donuts To Hogs - Which Brand Icons Might Be In Play? 4From Donuts To Hogs - Which Brand Icons Might Be In Play? 5From Donuts To Hogs - Which Brand Icons Might Be In Play? 6From Donuts To Hogs - Which Brand Icons Might Be In Play? 7From Donuts To Hogs - Which Brand Icons Might Be In Play? 8Valeritas Announces Appointment of New CFO 2Valeritas Announces Appointment of New CFO 3Carl Zeiss Offers Online Promotions 2
(Date:9/16/2014)... (17 September, 2014)More than $100 trillion in cumulative ... annual carbon dioxide (CO2)a 40 percent reduction of ... if the world expands public transportation, walking and ... released by the University of California, Davis, and ... , Further, an estimated 1.4 million early ...
(Date:9/16/2014)... us that we inherit certain traits from our parents ... how these genes play out by taking certain drugs ... exactly what a team of researchers at the Boston ... research of epigenetics research. , Epigenetics regulates gene ... and histone proteins, which prevent permanent mutations or alterations ...
(Date:9/16/2014)... that spelled doom for the dinosaurs 66 million years ... a much greater extent than their deciduous peers, according ... are published in the journal PLOS Biology . ... of thousands of fossilized leaves of angiosperms ... to reconstruct the ecology of a diverse plant community ...
Breaking Biology News(10 mins):Global shift away from cars saves US$100 trillion, eliminates 1,700 MT of CO2 pollution 2Global shift away from cars saves US$100 trillion, eliminates 1,700 MT of CO2 pollution 3Global shift away from cars saves US$100 trillion, eliminates 1,700 MT of CO2 pollution 4Global shift away from cars saves US$100 trillion, eliminates 1,700 MT of CO2 pollution 5Epigenetic drugs: A hope to treat cancer resistance and reduce cancer relapse? 2Epigenetic drugs: A hope to treat cancer resistance and reduce cancer relapse? 3Meteorite that doomed dinosaurs remade forests 2Meteorite that doomed dinosaurs remade forests 3Meteorite that doomed dinosaurs remade forests 4
... Louis, MO, USA, February 1, 2009 A special ... Journal of the American Dietetic Association presents findings ... Study (SNDA-III), conducted by Mathematica Policy Research, Inc., as ... Sponsored by the Food and Nutrition Service of the ...
... leaders in tropical biology and conservation, William F. Laurance, ... and Thomas E. Lovejoy, research associate at the Institute ... Center for Science, Economics and the Environment, have won ... in Ecology and Conservation Biology, announced on 30 Jan. ...
... LA Huijing Xia, PhD, a postdoctoral research associate ... of Pharmacology at LSU Health Sciences Center New Orleans, ... a recently identified enzyme in the brain plays a ... pressure. The LSUHSC research team showed that Angiotensin-converting enzyme ...
Cached Biology News:Results of the third school nutrition dietary assessment study published 2Results of the third school nutrition dietary assessment study published 3Results of the third school nutrition dietary assessment study published 4Smithsonian scientists receive coveted BBVA Ecology and Conservation Award 2LSUSHC researchers find potential new target for hypertension treatment 2
... that it uses a deep-UV deuterium bulb, which ... with a shutter (controlled via a TTL signal ... DH-2000 Deuterium Tungsten Halogen Light Source combines ... light sources in a single optical path. The ...
One controller two vessel system suitable for early stage of fermentation, and small scale, Application : cultivation of microorganisms and human or animal cells...
... These handy dispensers save space and ... and other garb. They are the ... parts used in labs, processing and ... charges and the particles they attract. ...
... used to reveal two distinct antigens in ... a Zymed polymer double staining detection method ... same human cell or tissue sample with ... using two different primary antibodies from mouse ...
Biology Products: